매사추세츠의 골수형성이상증후군 임상 시험
골수형성이상증후군 관련 연구 22개가 매사추세츠 내 여러 지역에서 참여자를 모집하고 있습니다.
매사추세츠의 도시
공식 연구 텍스트(영어)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- 외 1개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05564390Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06577441Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT03471260Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Massachusetts General Hospital, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
피험자 모집 중1상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 7. 28. 업데이트됨 · NCT07020533Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 17. 업데이트됨 · NCT06138587SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 17. 업데이트됨 · NCT03113643A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
12세 이상 · 모든 성별 · 2026. 6. 17. 업데이트됨 · NCT04024761Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- 외 2개
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 5. 7. 업데이트됨 · NCT02269592A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 4. 30. 업데이트됨 · NCT04256317Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 8. 업데이트됨 · NCT06419634A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
1세 ~ 40세 · 모든 성별 · 2026. 3. 12. 업데이트됨 · NCT05292664CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
피험자 모집 중2상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 3. 10. 업데이트됨 · NCT06059391SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774IS-free Treg HaploHCT
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
18세 ~ 75세 · 모든 성별 · 2025. 10. 20. 업데이트됨 · NCT04678401HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2025. 9. 17. 업데이트됨 · NCT06487247Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
- Shwachman-Diamond Syndrome Alliance Inc., Woburn
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 5. 31. 업데이트됨 · NCT06999954Study of REM-422 in Patients With AML or Higher Risk MDS
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 4. 23. 업데이트됨 · NCT06297941Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 4. 15. 업데이트됨 · NCT06462365ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.